| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.01.2026 | 676 | Xetra Newsboard | he following instruments on Boerse Frankfurt do have their last trading day on 30.01.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.01.2026.ISIN NameCA3397643006 FLORA... ► Artikel lesen | |
| 06:00 | Legales MDMA: Bioxyne geht nächsten Schritt | Small- & Micro Cap Investment | |||
| 08:13 | Breaking News: Tycoon für den Vorstand von NurExone! | bullVestor | |||
| Fr | Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification | 440 | PR Newswire | TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| Fr | Origin Agritech Limited: Origin Agritech Announces Fiscal Year 2025 Results | 178 | PR Newswire | Announces Filing of Annual Report on Form 20-F for Fiscal Year 2025
BEIJING, Jan. 30, 2026 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or... ► Artikel lesen | |
| Fr | NurExone Biologic Inc: NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise | 88 | GlobeNewswire (Europe) | TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company") today announced changes to its board of directors... ► Artikel lesen | |
| Fr | Tevogen Bio Inc: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders | 79 | GlobeNewswire (Europe) | WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate... ► Artikel lesen | |
| Fr | Olema Oncology Announces Departure of Chief Operating and Financial Officer | 46 | GlobeNewswire (Europe) | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| RECORDATI | 46,000 | 1,30 | +2,83 % | 0,63 | 24.11.2025 | |
| AMGEN | 288,20 | 7,99 | +2,77 % | 2,52 | 13.02.2026 | |
| BIO-TECHNE | 54,00 | 0,27 | +0,50 % | 0,08 | 17.11.2025 | |
| REGENERON PHARMACEUTICALS | 626,80 | 3,04 | +0,49 % | 0,88 | 20.11.2025 | |
| BIOGEN | 149,10 | 0,00 | 0,00 % | |||
| ENZO BIOCHEM | 0,388 | 0,00 | 0,00 % | |||
| MYRIAD GENETICS | 4,640 | 0,00 | 0,00 % | |||
| TRANSGENE | 0,878 | 0,00 | 0,00 % | |||
| INOVIO PHARMACEUTICALS | 1,370 | 0,00 | 0,00 % | |||
| INTEGRA LIFESCIENCES | 9,100 | 0,00 | 0,00 % |